Gilead Sciences vs Novo Nordisk

Gilead Sciences (GILD), health care, and Novo Nordisk (NVO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Gilead Sciences is worth $210.7B on the stock market and Novo Nordisk $179B: Gilead Sciences is valued at 18% more. Gilead Sciences's operating margin in its latest fiscal year was 34.0% and Novo Nordisk's 41.3%. Over the past year Gilead Sciences's share price has moved +31.8% and Novo Nordisk's -12.5%.

Key facts

Gilead Sciences market value
$210.7B
Novo Nordisk market value
$179B
Novo Nordisk P/E
10.3
Gilead Sciences revenue
$29.4BFY to 2025-12-31
Novo Nordisk revenue
$45.9BFY to 2025-12-31
Superinvestors holding both
2

Market values as of .

Gilead Sciences vs Novo Nordisk: every measure side by side
Measure Gilead Sciences Novo Nordisk
SectorHealth CareHealth Care
Country United States Denmark
Fiscal year ends2025-12-312025-12-31
Size
Market cap$210.7Bhigher$179Blower
Revenue$29.4Blower$45.9Bhigher
Earnings$8.5Blower$15.2Bhigher
Employees17,000lower68,794higher
Total assets$59Blower$80.6Bhigher
Valuation
P/E—10.3
P/S7.2higher3.9lower
P/B16.2—
Dividend yield1.94%—
Profitability
Operating margin34.0%lower41.3%higher
Balance sheet
Net assets$22.7Blower$28.8Bhigher
Total liabilities$36.4Blower$51.8Bhigher
Total debt$24.9Bhigher$19.4Blower
Cash on hand$7.6Bhigher$3.9Blower
Price change
Today+1.39%higher-2.37%lower
1 year+31.8%higher-12.5%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Gilead Sciences / Novo Nordisk). Who owns GILD · Who owns NVO

Further comparisons

Learn

Questions and answers

Which is bigger, Gilead Sciences or Novo Nordisk?

By market value, Gilead Sciences is the larger: $210.7B against $179B for Novo Nordisk. By revenue in its latest fiscal year, Novo Nordisk is the larger: $45.9B against $29.4B for Gilead Sciences.

Which has the higher operating margin?

Novo Nordisk: 41.3%, against 34.0% for Gilead Sciences. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Gilead Sciences: $24.9B, against $19.4B for Novo Nordisk. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Gilead Sciences and Novo Nordisk?

In their latest 13F filings, Dodge & Cox team and Jim Simons (1938–2024) hold both.

Cite this page

Funkfolio, “Gilead Sciences vs Novo Nordisk”, data as of 17 November 2026. https://funkfolio.com/compare/gild-vs-nvo

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.